Use of methotrexate in inflammatory bowel disease in 2014: A User’s Guide

Table 2 Evidence for induction of remission of ulcerative colitis with methotrexate

Study	Dose (mean)	Route	No. of patients	Study design	Follow-up (wk)	MTX response	MTX remission	Placebo response
Kozarek	25 mg	im	7	Open label	12	5/7 (71.40%)		N/A
Baron	15 mg	Oral	8	Open label	18	3/8 (37.5%)	0	N/A
Oren	12.5 mg	Oral	67	Placebo control	36	14/30 (46.7%)		18/37 (48.6%)
Egan	15 mg 25 mg	scsc	18 12	Open label	16	7/18 (39%) 4/12 (33%)	3/18 (17%) 2/12 (17%)	N/A N/A
Mate-Jimenez	15 mg	Oral	34	6-MP control	30		7/12 (58.30%)	11/14 (78.6%)
Paoluzi	12.5 mg	im	10 thiopurine resistant/intolerant	Open label	26	10/10 (100%)	6/10 (60%)	N/A
Cummings	19.9 mg mean	Oral	11 AZA failure 31 AZA intolerant	Retrospective	30	3/11 (27%) 18/31 (58%)	14/31	N/A
Nathan	20-25 mg	sc/ oral	23	Retrospective	N/A		11/23 (48%)	N/A
Wahed	10-25 mg	Oral, sc	9 thiopurine ineffective 23 thiopurine intolerant	Retrospective	26	7/9 (78%) 15/23 (65%)	N/A	N/A
Manosa	25 mg	Oral sc	7 33	Retrospective	26		24/40 (60%) remission	N/A
Saibeni	20 mg	Oral/ sc/im	23	Retrospective	N/A	11/23 (47.8%)		N/A
Khan	14 mg 25 mg	Oral sc/im	68 23	Retrospective	60	25/68 (37%) 7/23 (30%)		N/A

MTX: Methotrexate; CD: Crohn’s disease; AE: Adverse events; SC: Subcutaneous; PO: Oral; AZA: Azathioprine.